Cohance Lifesciences Limited (NSE:COHANCE)
325.35
+16.60 (5.38%)
Feb 18, 2026, 3:15 PM IST
Cohance Lifesciences Revenue
Cohance Lifesciences had revenue of 5.45B INR in the quarter ending December 31, 2025, with 77.29% growth. This brings the company's revenue in the last twelve months to 10.79B, up 2.90% year-over-year. In the fiscal year ending March 31, 2025, Cohance Lifesciences had annual revenue of 11.98B with 13.91% growth.
Revenue (ttm)
10.79B
Revenue Growth
+2.90%
P/S Ratio
10.95
Revenue / Employee
8.90M
Employees
1,212
Market Cap
118.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 11.98B | 1.46B | 13.91% |
| Mar 31, 2024 | 10.51B | -2.89B | -21.56% |
| Mar 31, 2023 | 13.40B | 201.07M | 1.52% |
| Mar 31, 2022 | 13.20B | 3.11B | 30.75% |
| Mar 31, 2021 | 10.10B | 1.76B | 21.10% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Piramal Pharma | 88.71B |
| Emcure Pharmaceuticals | 88.50B |
| Alembic Pharmaceuticals | 72.67B |
| Gland Pharma | 61.13B |
| Strides Pharma Science | 47.26B |
| NATCO Pharma | 45.63B |
| Akums Drugs and Pharmaceuticals | 42.60B |
| Eris Lifesciences | 30.65B |